We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
Hit the mark. Joop van Gerven and Justin Hay of CHDR discuss how carefully chosen biomarkers can easily be incorporated into early phase drug studies, providing guidance for important decisions concerning a drug’s future.